Oncodesign is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology, Inflammatory and Infectious Diseases (incl. COVID-19).Benefiting from multi-disciplinary teams and seasoned management with long-standing experience in pharmaceutical industry and innovative services, DRIVE-IDDS™ is an integrated drug discovery engine configured to discover, generate and accelerate the entry of new chemical entities into the clinic. DRIVE-IDDS™ from Hit Finding to IND filing encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology/pharmaco-imaging and safety assessment all applied in one-stop shop to drug discovery programs.

You may also take advantage of our SOLO solutions, a wide range of distinct and diversified services for new therapies assessment.

Oncodesign’s headquarters are based in Dijon, France, with an additional R&D center in the Paris Saclay cluster (ex-GSK R&D Site). Oncodesign has 240 employees and subsidiaries in Canada and the USA.